Inspira Technologies OXY B.H.N. Ltd. has made progress on $22.5 million and $27 million binding purchase orders, moving to the final budgetary validation stage. Approximately 91% of the orders have cleared commercial and administrative reviews, with payment and revenue recognition expected in 2026. CEO Dagi Ben-Noon emphasizes converting backlog into revenue. Inspira specializes in respiratory support and blood monitoring devices, with plans for the FDA-cleared INSPIRA™ ART500 system. The company is optimistic about future growth and development. For more information, visit their website. The company urges caution with forward-looking statements and emphasizes risk factors.

Read more at GlobeNewswire: Inspira Advances to Final Governmental Budgetary Validation